Gapping up
In reaction to strong earnings/guidance: SNSS +19.4%, SAIC +6.4%, STLD +3.1%, HNI +1.1%
M&A news: PWE +69.6% (confirmed $1.1 bln in asset sales, including sale of Saskatchewan assets for $975 mln), LNKD+47.2% (to be acquired my Microsoft (MSFT) for $196/share ), SYMC +4.2% (will acquire Blue Coat for ~$4.651 bln in cash),RDY +0.9% (to acquire Teva's (TEVA) portfolio of 8 ANDAs for $350 mln)
Select metals/mining stocks trading higher: MUX +6.8%, HMY +3.6%, AUY +3.2%, ABX +2.5%, GG +2.2%, NEM+2.1%, SLW +1.8%, GDX +1.8%, AU +1.6%
Other news: EBIO +79.1% (to grant an exclusive license to Roche (RHHBY) to develop/commercialize EBI-031; receives an upfront payment of $7.5 mln, along with potential milestone payments of up to $262.5 mln), SNSS +19.5% (presents updated results from an ongoing Phase 1b/2 trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia and high-risk myelodysplastic), AGIO +9.2% (presents data for Phase 2 DRIVE-PK study of AG-348 demonstrating rapid and sustained hemoglobin increases), SWHC +7.9% (speculation of tighter gun control laws; suggests ramp in near-term sales), MNKD +5.9% (presents Late-Breaking data Afrezza confirming faster onset and shorter duration of action compared to mealtime insulins), SUNW +5.5% (updated corporate presentation reaffirms FY16 target of $100 mln in revs vs the $103 mln single analyst estimate), TTNP +4.7% (receives $15 mln milestone payment from development and commercialization partner Braeburn Pharmaceuticals following FDA approval of Probuphine), RGR +4.3% (speculation of tighter gun control laws; suggests ramp in near-term sales), AMRN +4.2% (reports data for Vascepa that indicated reductions in potentially atherogenic lipid parameters), GALE +3.4% (presents combined safety data from its GALE-401 clinical trials), VRX+2.7% (CEO disclosed purchase of 202K shares worth ~$4.9 mln; Pershing Square affirms unchanged 9.0% active stake, updating on recent transactions), VICL +2.4% (insider purchase by CEO)
Analyst comments: ON +1.5% (upgraded to Overweight at Pacific Crest), ENDP +1.2% (upgraded to Neutral at Mizuho)
In reaction to strong earnings/guidance: SNSS +19.4%, SAIC +6.4%, STLD +3.1%, HNI +1.1%
M&A news: PWE +69.6% (confirmed $1.1 bln in asset sales, including sale of Saskatchewan assets for $975 mln), LNKD+47.2% (to be acquired my Microsoft (MSFT) for $196/share ), SYMC +4.2% (will acquire Blue Coat for ~$4.651 bln in cash),RDY +0.9% (to acquire Teva's (TEVA) portfolio of 8 ANDAs for $350 mln)
Select metals/mining stocks trading higher: MUX +6.8%, HMY +3.6%, AUY +3.2%, ABX +2.5%, GG +2.2%, NEM+2.1%, SLW +1.8%, GDX +1.8%, AU +1.6%
Other news: EBIO +79.1% (to grant an exclusive license to Roche (RHHBY) to develop/commercialize EBI-031; receives an upfront payment of $7.5 mln, along with potential milestone payments of up to $262.5 mln), SNSS +19.5% (presents updated results from an ongoing Phase 1b/2 trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia and high-risk myelodysplastic), AGIO +9.2% (presents data for Phase 2 DRIVE-PK study of AG-348 demonstrating rapid and sustained hemoglobin increases), SWHC +7.9% (speculation of tighter gun control laws; suggests ramp in near-term sales), MNKD +5.9% (presents Late-Breaking data Afrezza confirming faster onset and shorter duration of action compared to mealtime insulins), SUNW +5.5% (updated corporate presentation reaffirms FY16 target of $100 mln in revs vs the $103 mln single analyst estimate), TTNP +4.7% (receives $15 mln milestone payment from development and commercialization partner Braeburn Pharmaceuticals following FDA approval of Probuphine), RGR +4.3% (speculation of tighter gun control laws; suggests ramp in near-term sales), AMRN +4.2% (reports data for Vascepa that indicated reductions in potentially atherogenic lipid parameters), GALE +3.4% (presents combined safety data from its GALE-401 clinical trials), VRX+2.7% (CEO disclosed purchase of 202K shares worth ~$4.9 mln; Pershing Square affirms unchanged 9.0% active stake, updating on recent transactions), VICL +2.4% (insider purchase by CEO)
Analyst comments: ON +1.5% (upgraded to Overweight at Pacific Crest), ENDP +1.2% (upgraded to Neutral at Mizuho)